Click for best price
Vaccines Administered Orally Market Size, Share 2022
Market Analysis and Insights: Global Vaccines Administered Orally Market
The global Vaccines Administered Orally market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Vaccines Administered Orally market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Vaccines Administered Orally market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Vaccines Administered Orally market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Vaccines Administered Orally market.
Global Vaccines Administered Orally Scope and Market Size
Vaccines Administered Orally market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Vaccines Administered Orally market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Human
Animal
Segment by Application
Public
Private
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Vaccines Administered Orally product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Vaccines Administered Orally, with price, sales, revenue, and global market share of Vaccines Administered Orally from 2019 to 2022.
Chapter 3, the Vaccines Administered Orally competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vaccines Administered Orally breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Vaccines Administered Orally market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Vaccines Administered Orally.
Chapter 13, 14, and 15, to describe Vaccines Administered Orally sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Vaccines Administered Orally Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Vaccines Administered Orally Market Insights and Forecast to 2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
110 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Vaccines Administered Orally Product Introduction
1.2 Market by Type
1.2.1 Global Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Human
1.2.3 Animal
1.3 Market by Application
1.3.1 Global Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Vaccines Administered Orally Sales Estimates and Forecasts 2017-2028
2.2 Global Vaccines Administered Orally Revenue Estimates and Forecasts 2017-2028
2.3 Global Vaccines Administered Orally Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Vaccines Administered Orally Sales by Region
2.4.1 Global Vaccines Administered Orally Sales by Region (2017-2022)
2.4.2 Global Sales Vaccines Administered Orally by Region (2023-2028)
2.5 Global Vaccines Administered Orally Revenue by Region
2.5.1 Global Vaccines Administered Orally Revenue by Region (2017-2022)
2.5.2 Global Vaccines Administered Orally Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Vaccines Administered Orally Sales by Manufacturers
3.1.1 Global Top Vaccines Administered Orally Manufacturers by Sales (2017-2022)
3.1.2 Global Vaccines Administered Orally Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaccines Administered Orally in 2021
3.2 Global Vaccines Administered Orally Revenue by Manufacturers
3.2.1 Global Vaccines Administered Orally Revenue by Manufacturers (2017-2022)
3.2.2 Global Vaccines Administered Orally Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Vaccines Administered Orally Revenue in 2021
3.3 Global Vaccines Administered Orally Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Vaccines Administered Orally Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaccines Administered Orally Sales by Type
4.1.1 Global Vaccines Administered Orally Historical Sales by Type (2017-2022)
4.1.2 Global Vaccines Administered Orally Forecasted Sales by Type (2023-2028)
4.1.3 Global Vaccines Administered Orally Sales Market Share by Type (2017-2028)
4.2 Global Vaccines Administered Orally Revenue by Type
4.2.1 Global Vaccines Administered Orally Historical Revenue by Type (2017-2022)
4.2.2 Global Vaccines Administered Orally Forecasted Revenue by Type (2023-2028)
4.2.3 Global Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
4.3 Global Vaccines Administered Orally Price by Type
4.3.1 Global Vaccines Administered Orally Price by Type (2017-2022)
4.3.2 Global Vaccines Administered Orally Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Vaccines Administered Orally Sales by Application
5.1.1 Global Vaccines Administered Orally Historical Sales by Application (2017-2022)
5.1.2 Global Vaccines Administered Orally Forecasted Sales by Application (2023-2028)
5.1.3 Global Vaccines Administered Orally Sales Market Share by Application (2017-2028)
5.2 Global Vaccines Administered Orally Revenue by Application
5.2.1 Global Vaccines Administered Orally Historical Revenue by Application (2017-2022)
5.2.2 Global Vaccines Administered Orally Forecasted Revenue by Application (2023-2028)
5.2.3 Global Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
5.3 Global Vaccines Administered Orally Price by Application
5.3.1 Global Vaccines Administered Orally Price by Application (2017-2022)
5.3.2 Global Vaccines Administered Orally Price Forecast by Application (2023-2028)
6 North America
6.1 North America Vaccines Administered Orally Market Size by Type
6.1.1 North America Vaccines Administered Orally Sales by Type (2017-2028)
6.1.2 North America Vaccines Administered Orally Revenue by Type (2017-2028)
6.2 North America Vaccines Administered Orally Market Size by Application
6.2.1 North America Vaccines Administered Orally Sales by Application (2017-2028)
6.2.2 North America Vaccines Administered Orally Revenue by Application (2017-2028)
6.3 North America Vaccines Administered Orally Market Size by Country
6.3.1 North America Vaccines Administered Orally Sales by Country (2017-2028)
6.3.2 North America Vaccines Administered Orally Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Vaccines Administered Orally Market Size by Type
7.1.1 Europe Vaccines Administered Orally Sales by Type (2017-2028)
7.1.2 Europe Vaccines Administered Orally Revenue by Type (2017-2028)
7.2 Europe Vaccines Administered Orally Market Size by Application
7.2.1 Europe Vaccines Administered Orally Sales by Application (2017-2028)
7.2.2 Europe Vaccines Administered Orally Revenue by Application (2017-2028)
7.3 Europe Vaccines Administered Orally Market Size by Country
7.3.1 Europe Vaccines Administered Orally Sales by Country (2017-2028)
7.3.2 Europe Vaccines Administered Orally Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vaccines Administered Orally Market Size by Type
8.1.1 Asia Pacific Vaccines Administered Orally Sales by Type (2017-2028)
8.1.2 Asia Pacific Vaccines Administered Orally Revenue by Type (2017-2028)
8.2 Asia Pacific Vaccines Administered Orally Market Size by Application
8.2.1 Asia Pacific Vaccines Administered Orally Sales by Application (2017-2028)
8.2.2 Asia Pacific Vaccines Administered Orally Revenue by Application (2017-2028)
8.3 Asia Pacific Vaccines Administered Orally Market Size by Region
8.3.1 Asia Pacific Vaccines Administered Orally Sales by Region (2017-2028)
8.3.2 Asia Pacific Vaccines Administered Orally Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Vaccines Administered Orally Market Size by Type
9.1.1 Latin America Vaccines Administered Orally Sales by Type (2017-2028)
9.1.2 Latin America Vaccines Administered Orally Revenue by Type (2017-2028)
9.2 Latin America Vaccines Administered Orally Market Size by Application
9.2.1 Latin America Vaccines Administered Orally Sales by Application (2017-2028)
9.2.2 Latin America Vaccines Administered Orally Revenue by Application (2017-2028)
9.3 Latin America Vaccines Administered Orally Market Size by Country
9.3.1 Latin America Vaccines Administered Orally Sales by Country (2017-2028)
9.3.2 Latin America Vaccines Administered Orally Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Vaccines Administered Orally Market Size by Type
10.1.1 Middle East and Africa Vaccines Administered Orally Sales by Type (2017-2028)
10.1.2 Middle East and Africa Vaccines Administered Orally Revenue by Type (2017-2028)
10.2 Middle East and Africa Vaccines Administered Orally Market Size by Application
10.2.1 Middle East and Africa Vaccines Administered Orally Sales by Application (2017-2028)
10.2.2 Middle East and Africa Vaccines Administered Orally Revenue by Application (2017-2028)
10.3 Middle East and Africa Vaccines Administered Orally Market Size by Country
10.3.1 Middle East and Africa Vaccines Administered Orally Sales by Country (2017-2028)
10.3.2 Middle East and Africa Vaccines Administered Orally Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Corporation Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Lanzhou Institute Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Corporation Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Serum Institute Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Corporation Information
11.6.2 Valneva Overview
11.6.3 Valneva Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Valneva Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Corporation Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shanghai United Cell Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Corporation Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bibcol Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Corporation Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 PaxVax Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Corporation Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Vabiotech Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Corporation Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Tiantan Biological Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Corporation Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 EuBiologics Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Corporation Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Panacea Biotec Ltd Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Corporation Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Bio-Med Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaccines Administered Orally Industry Chain Analysis
12.2 Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccines Administered Orally Production Mode & Process
12.4 Vaccines Administered Orally Sales and Marketing
12.4.1 Vaccines Administered Orally Sales Channels
12.4.2 Vaccines Administered Orally Distributors
12.5 Vaccines Administered Orally Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Vaccines Administered Orally Industry Trends
13.2 Vaccines Administered Orally Market Drivers
13.3 Vaccines Administered Orally Market Challenges
13.4 Vaccines Administered Orally Market Restraints
14 Key Findings in The Global Vaccines Administered Orally Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Human
Table 3. Major Manufacturers of Animal
Table 4. Global Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Vaccines Administered Orally Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 7. Global Vaccines Administered Orally Sales Market Share by Region (2017-2022)
Table 8. Global Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
Table 9. Global Vaccines Administered Orally Sales Market Share by Region (2023-2028)
Table 10. Global Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Vaccines Administered Orally Revenue Market Share by Region (2017-2022)
Table 12. Global Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Vaccines Administered Orally Revenue Market Share by Region (2023-2028)
Table 14. Global Vaccines Administered Orally Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Vaccines Administered Orally Sales Share by Manufacturers (2017-2022)
Table 16. Global Vaccines Administered Orally Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
Table 18. Vaccines Administered Orally Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Vaccines Administered Orally by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccines Administered Orally as of 2021)
Table 21. Vaccines Administered Orally Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Vaccines Administered Orally Product Offered
Table 23. Date of Manufacturers Enter into Vaccines Administered Orally Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 26. Global Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 27. Global Vaccines Administered Orally Sales Share by Type (2017-2022)
Table 28. Global Vaccines Administered Orally Sales Share by Type (2023-2028)
Table 29. Global Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Vaccines Administered Orally Revenue Share by Type (2017-2022)
Table 32. Global Vaccines Administered Orally Revenue Share by Type (2023-2028)
Table 33. Vaccines Administered Orally Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Vaccines Administered Orally Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 36. Global Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 37. Global Vaccines Administered Orally Sales Share by Application (2017-2022)
Table 38. Global Vaccines Administered Orally Sales Share by Application (2023-2028)
Table 39. Global Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Vaccines Administered Orally Revenue Share by Application (2017-2022)
Table 42. Global Vaccines Administered Orally Revenue Share by Application (2023-2028)
Table 43. Vaccines Administered Orally Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Vaccines Administered Orally Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 46. North America Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 47. North America Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 50. North America Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 51. North America Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 54. North America Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 55. North America Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 58. Europe Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 59. Europe Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 62. Europe Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 63. Europe Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 66. Europe Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 67. Europe Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 105. Merck Corporation Information
Table 106. Merck Description and Major Businesses
Table 107. Merck Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Merck Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Merck Recent Developments
Table 110. GSK Corporation Information
Table 111. GSK Description and Major Businesses
Table 112. GSK Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. GSK Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GSK Recent Developments
Table 115. Sanofi Corporation Information
Table 116. Sanofi Description and Major Businesses
Table 117. Sanofi Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Sanofi Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Sanofi Recent Developments
Table 120. Lanzhou Institute Corporation Information
Table 121. Lanzhou Institute Description and Major Businesses
Table 122. Lanzhou Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. Lanzhou Institute Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Lanzhou Institute Recent Developments
Table 125. Serum Institute Corporation Information
Table 126. Serum Institute Description and Major Businesses
Table 127. Serum Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. Serum Institute Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Serum Institute Recent Developments
Table 130. Valneva Corporation Information
Table 131. Valneva Description and Major Businesses
Table 132. Valneva Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. Valneva Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Valneva Recent Developments
Table 135. Shanghai United Cell Corporation Information
Table 136. Shanghai United Cell Description and Major Businesses
Table 137. Shanghai United Cell Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Shanghai United Cell Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Shanghai United Cell Recent Developments
Table 140. Bibcol Corporation Information
Table 141. Bibcol Description and Major Businesses
Table 142. Bibcol Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 143. Bibcol Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Bibcol Recent Developments
Table 145. PaxVax Corporation Information
Table 146. PaxVax Description and Major Businesses
Table 147. PaxVax Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 148. PaxVax Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. PaxVax Recent Developments
Table 150. Vabiotech Corporation Information
Table 151. Vabiotech Description and Major Businesses
Table 152. Vabiotech Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 153. Vabiotech Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Vabiotech Recent Developments
Table 155. Tiantan Biological Corporation Information
Table 156. Tiantan Biological Description and Major Businesses
Table 157. Tiantan Biological Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 158. Tiantan Biological Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. Tiantan Biological Recent Developments
Table 160. EuBiologics Corporation Information
Table 161. EuBiologics Description and Major Businesses
Table 162. EuBiologics Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 163. EuBiologics Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. EuBiologics Recent Developments
Table 165. Panacea Biotec Ltd Corporation Information
Table 166. Panacea Biotec Ltd Description and Major Businesses
Table 167. Panacea Biotec Ltd Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 168. Panacea Biotec Ltd Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. Panacea Biotec Ltd Recent Developments
Table 170. Bio-Med Corporation Information
Table 171. Bio-Med Description and Major Businesses
Table 172. Bio-Med Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 173. Bio-Med Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 174. Bio-Med Recent Developments
Table 175. Halfkin Bio-Pharmaceuticals Corporation Information
Table 176. Halfkin Bio-Pharmaceuticals Description and Major Businesses
Table 177. Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 178. Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 179. Halfkin Bio-Pharmaceuticals Recent Developments
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Vaccines Administered Orally Distributors List
Table 183. Vaccines Administered Orally Customers List
Table 184. Vaccines Administered Orally Market Trends
Table 185. Vaccines Administered Orally Market Drivers
Table 186. Vaccines Administered Orally Market Challenges
Table 187. Vaccines Administered Orally Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccines Administered Orally Product Picture
Figure 3. Global Vaccines Administered Orally Market Share by Type in 2021 & 2028
Figure 3. Human Product Picture
Figure 4. Animal Product Picture
Figure 5. Global Vaccines Administered Orally Market Share by Application in 2021 & 2028
Figure 6. Public
Figure 7. Private
Figure 8. Vaccines Administered Orally Report Years Considered
Figure 9. Global Vaccines Administered Orally Sales 2017-2028 (K Units)
Figure 10. Global Vaccines Administered Orally Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Vaccines Administered Orally Revenue 2017-2028 (US$ Million)
Figure 12. Global Vaccines Administered Orally Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Vaccines Administered Orally Sales Market Share by Region (2017-2022)
Figure 14. Global Vaccines Administered Orally Sales Market Share by Region (2023-2028)
Figure 15. North America Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
Figure 16. North America Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
Figure 18. Europe Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
Figure 20. Asia-Pacific Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
Figure 22. Latin America Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
Figure 24. Middle East & Africa Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Vaccines Administered Orally Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Vaccines Administered Orally in the World: Market Share by Vaccines Administered Orally Revenue in 2021
Figure 27. Global Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 29. Global Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 30. Global Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 31. Global Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 32. North America Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 33. North America Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 34. North America Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 35. North America Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 36. North America Vaccines Administered Orally Sales Share by Country (2017-2028)
Figure 37. North America Vaccines Administered Orally Revenue Share by Country (2017-2028)
Figure 38. U.S. Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 41. Europe Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 42. Europe Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 43. Europe Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 44. Europe Vaccines Administered Orally Sales Share by Country (2017-2028)
Figure 45. Europe Vaccines Administered Orally Revenue Share by Country (2017-2028)
Figure 46. Germany Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 47. France Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Vaccines Administered Orally Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Vaccines Administered Orally Revenue Share by Region (2017-2028)
Figure 57. China Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 60. India Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 62. Taiwan Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 66. Philippines Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 68. Latin America Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 70. Latin America Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Vaccines Administered Orally Sales Share by Country (2017-2028)
Figure 72. Latin America Vaccines Administered Orally Revenue Share by Country (2017-2028)
Figure 73. Mexico Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Vaccines Administered Orally Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Vaccines Administered Orally Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Vaccines Administered Orally Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Vaccines Administered Orally Revenue Share by Country (2017-2028)
Figure 82. Turkey Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 84. U.A.E Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
Figure 85. Vaccines Administered Orally Value Chain
Figure 86. Vaccines Administered Orally Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
